Monitor for the final European Commission decision expected in Q2 2026, which could trigger positive price movement. The approval would open a new market for Joenja as the first treatment for APDS in Europe.
PHAR drugs
PHAR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 27 $16.31entry
- T+1 · 8mo ago −1.84%α −1.48% · $16.01
- T+5 · 8mo ago +1.16%α −2.70% · $16.50
- T+20 · 7mo ago +3.74%α −9.00% · $16.92
- T+60 · 5mo ago −20.23%α −36.30% · $13.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3K) syndrome (APDS) in adult and pediatric patients 12 years and older. If approved by the European Commission, Joenja would become the first approved treatment for APDS in the European Union.
Key Facts
- CHMP adopted a positive opinion recommending marketing authorization for Joenja (leniolisib) for APDS treatment
- Final European Commission decision expected in Q2 2026
- If approved, Joenja would be the first treatment for APDS in the EU
- Approval would be valid in all 27 EU member states plus Norway, Iceland, and Liechtenstein
- Joenja is already approved in the US, UK, Japan, Australia, and Israel
- Decision based on Phase III clinical trial data showing statistically significant impact
Financial Impact
Potential for significant revenue growth if approved in EU market
Risk Factors
- European Commission could reject the recommendation despite positive CHMP opinion
- Commercial uptake may be limited due to APDS being a rare disease affecting 1-2 people per million
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000012 |
| Document: 0001828316-26-000012-index-headers.html | 0001828316-26-000012 |
| Document: 0001828316-26-000012-index.html | 0001828316-26-000012 |
| Document: 0001828316-26-000012.txt | 0001828316-26-000012 |
Track record
18 reports on PHAR
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Oct 27, 202620d ago 6-K Bullish 6/10 No price data
- Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
- Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
- Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
- Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers